Invivyd (IVVD) Competitors $1.25 -0.01 (-0.40%) As of 10:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVVD vs. AQST, ESPR, IVA, RAPP, CYRX, ZVRA, PRME, BCYC, EOLS, and REPLShould you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Aquestive Therapeutics (AQST), Esperion Therapeutics (ESPR), Inventiva (IVA), Rapport Therapeutics (RAPP), CryoPort (CYRX), Zevra Therapeutics (ZVRA), Prime Medicine (PRME), Bicycle Therapeutics (BCYC), Evolus (EOLS), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry. Invivyd vs. Its Competitors Aquestive Therapeutics Esperion Therapeutics Inventiva Rapport Therapeutics CryoPort Zevra Therapeutics Prime Medicine Bicycle Therapeutics Evolus Replimune Group Invivyd (NASDAQ:IVVD) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership. Do analysts prefer IVVD or AQST? Invivyd presently has a consensus price target of $3.18, indicating a potential upside of 153.65%. Aquestive Therapeutics has a consensus price target of $10.29, indicating a potential upside of 110.13%. Given Invivyd's stronger consensus rating and higher possible upside, analysts clearly believe Invivyd is more favorable than Aquestive Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Aquestive Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of IVVD or AQST? 70.4% of Invivyd shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 25.4% of Invivyd shares are owned by company insiders. Comparatively, 7.9% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor IVVD or AQST? In the previous week, Aquestive Therapeutics had 2 more articles in the media than Invivyd. MarketBeat recorded 6 mentions for Aquestive Therapeutics and 4 mentions for Invivyd. Aquestive Therapeutics' average media sentiment score of 1.29 beat Invivyd's score of 0.72 indicating that Aquestive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aquestive Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is IVVD or AQST more profitable? Aquestive Therapeutics has a net margin of -147.38% compared to Invivyd's net margin of -238.33%. Aquestive Therapeutics' return on equity of 0.00% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets Invivyd-238.33% -177.89% -90.96% Aquestive Therapeutics -147.38%N/A -63.87% Which has higher earnings & valuation, IVVD or AQST? Aquestive Therapeutics has higher revenue and earnings than Invivyd. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivyd$25.38M5.94-$169.93M-$0.92-1.36Aquestive Therapeutics$57.56M8.48-$44.14M-$0.70-6.99 Which has more volatility and risk, IVVD or AQST? Invivyd has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. SummaryAquestive Therapeutics beats Invivyd on 11 of the 16 factors compared between the two stocks. Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVVD vs. The Competition Export to ExcelMetricInvivydMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$150.78M$3.14B$5.75B$10.29BDividend YieldN/A2.36%5.88%4.63%P/E Ratio-1.3621.4176.3426.62Price / Sales5.94452.95525.65124.40Price / CashN/A45.4037.1760.46Price / Book2.249.6913.726.30Net Income-$169.93M-$53.02M$3.29B$270.83M7 Day Performance-2.71%1.61%1.31%2.35%1 Month Performance77.49%5.27%5.06%6.69%1 Year Performance13.06%9.58%81.63%27.20% Invivyd Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVVDInvivyd3.4575 of 5 stars$1.26-0.4%$3.18+153.7%+10.5%$150.78M$25.38M-1.36100Short Interest ↑AQSTAquestive Therapeutics2.2902 of 5 stars$5.01-7.6%$10.29+105.3%-1.8%$540.50M$57.56M-7.16160Positive NewsESPREsperion Therapeutics3.8079 of 5 stars$2.51-6.3%$7.00+178.9%+57.4%$540.35M$332.31M-5.12200IVAInventiva3.1542 of 5 stars$5.37-3.6%$14.83+176.2%+140.7%$532.84M$9.95M0.00100Short Interest ↑Gap DownRAPPRapport Therapeutics3.0852 of 5 stars$31.47+119.2%$31.00-1.5%+39.4%$524.11MN/A-12.59N/AAnalyst ForecastGap UpHigh Trading VolumeCYRXCryoPort3.9763 of 5 stars$10.04-3.0%$12.00+19.5%+8.4%$518.19M$228.38M7.551,186Positive NewsZVRAZevra Therapeutics2.9805 of 5 stars$8.33-6.9%$23.71+184.7%-6.7%$502.41M$23.61M-39.6720News CoveragePositive NewsPRMEPrime Medicine3.3294 of 5 stars$3.89+4.6%$8.92+129.2%+24.9%$500.62M$4.96M-1.90234Gap UpBCYCBicycle Therapeutics3.1086 of 5 stars$7.00-2.2%$22.22+217.5%-72.2%$495.86M$35.28M-1.99240Positive NewsEOLSEvolus4.1276 of 5 stars$7.61-0.7%$21.25+179.2%-61.1%$495.49M$266.27M-7.77170Positive NewsREPLReplimune Group3.8619 of 5 stars$6.04-4.6%$6.50+7.6%-44.6%$494.09MN/A-1.86210 Related Companies and Tools Related Companies AQST Competitors ESPR Competitors IVA Competitors RAPP Competitors CYRX Competitors ZVRA Competitors PRME Competitors BCYC Competitors EOLS Competitors REPL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVVD) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
